MedTrace Logo

Pharmacokinetics of XueBiJing in Patients With Sepsis

NCT03475732 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2021-01-05

No results posted yet for this study

Summary

Pharmacokinetics and disposition of XueBiJing compounds in patients with sepsis

Conditions

  • Sepsis
  • Septic Shock
  • Community Acquired Pneumonia

Interventions

DRUG

XueBiJing injection

100mL XueBiJing injection (dissolved with 100 mL of 0.9% normal saline),intravenous infusion for 1.25 h, q12h for 5 days

Sponsors & Collaborators

  • Chinese Academy of Sciences

    collaborator OTHER_GOV

  • Southeast University, China

    lead OTHER

Principal Investigators

  • Chuan Li, Doctor · Shanghai Institute of Materia Medica, Chinese Academy of Sciences,China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-18
Primary Completion
2019-06-30
Completion
2019-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03475732 on ClinicalTrials.gov